Company news

Regenxbio Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

REGENXBIO Announces Participation at the 2023 Wedbush PacGrow Healthcare Conference

July 31, 2023

REGENXBIO to Host Conference Call on August 2 to Discuss Second Quarter 2023 Financial Results and Recent Operational Highlights

July 25, 2023

REGENXBIO Announces Upcoming Presentations at the American Society of Retina Specialists Annual Scientific Meeting

July 23, 2023

REGENXBIO Highlights AAV Pipeline with Interim Results from Retinal and Duchenne Programs at its Virtual Investor Day on July 11, 2023

July 10, 2023

REGENXBIO to Host Virtual Investor Day Highlighting AAV Pipeline Programs with Upcoming Interim Trial Updates

June 26, 2023

REGENXBIO and University of Pennsylvania File NAV® Technology Patent Infringement Lawsuit

June 19, 2023

REGENXBIO Announces Presentation at the Jefferies Global Healthcare Conference

May 31, 2023

REGENXBIO Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RGX-121 Gene Therapy for Hunter Syndrome

May 22, 2023

REGENXBIO Announces Presentation at the Barclays Gene Editing & Therapy Summit 2023

May 21, 2023

REGENXBIO Announces NAV® Technology Platform Will Support Bespoke Gene Therapy Consortium's First Rare Disease Clinical Portfolio

May 15, 2023

REGENXBIO Reports First Quarter 2023 Financial Results and Recent Operational Highlights

May 2, 2023

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 26th Annual Meeting

May 1, 2023

REGENXBIO to Host Conference Call on May 3 to Discuss First Quarter 2023 Financial Results and Recent Operational Highlights

April 25, 2023

REGENXBIO Announces Presentation at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

April 17, 2023

REGENXBIO Receives FDA Fast Track Designation for RGX-202, a Novel Gene Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy

April 10, 2023

REGENXBIO Reports Fourth Quarter 2022 and Full-Year 2022 Financial Results and Recent Operational Highlights

February 27, 2023

Additional Positive Interim Data from Phase I/II Trial of REGENXBIO'S RGX-111 for the Treatment of Severe MPS I Presented at WORLDSymposium™

February 23, 2023

Additional Positive Interim Data from Phase I/II/III CAMPSIITE™ Trial of REGENXBIO's RGX-121 for the Treatment of MPS II (Hunter Syndrome) Presented at 19th Annual WORLDSymposiumTM

February 21, 2023

REGENXBIO to Host Conference Call on February 28 to Discuss Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights

February 20, 2023

REGENXBIO Announces Presentations at the 19th Annual WORLDSymposium™ 2023

February 16, 2023

REGENXBIO Presents Interim Data from Phase II Bridging Study Evaluating the Clinical Performance of RGX-314 Using the NAVXpress™ Manufacturing Platform Process

February 10, 2023

REGENXBIO Announces Presentation at the Virtual SVB Securities Global Biopharma Conference

February 7, 2023

REGENXBIO Announces Presentations at the Angiogenesis, Exudation, and Degeneration 2023 Conference

February 5, 2023

REGENXBIO Announces Phase I/II Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy, is Active and Recruiting Patients

January 22, 2023

REGENXBIO announces senior leadership promotions

January 8, 2023

REGENXBIO Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference

January 2, 2023

REGENXBIO Reports Update on Advancement of Programs for CLN2 Disease

December 20, 2022

REGENXBIO Announces Completion of Dosing in the Phase I/II Trial of RGX-111 for the Treatment of Severe MPS I

December 7, 2022

REGENXBIO Reports Third Quarter 2022 Financial Results and Recent Operational Highlights

November 2, 2022

REGENXBIO Presents Positive Interim Data from and the Expansion of Phase II ALTITUDE® Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery

November 2, 2022

REGENXBIO to Host Conference Call on November 3 to Discuss Third Quarter 2022 Financial Results, Recent Operational Highlights and Interim Data from Phase II ALTITUDE® Trial of RGX-314 for the Treatment of Diabetic Retinopathy

October 26, 2022

REGENXBIO Announces Additional Positive Interim Data from Trials of RGX-314 for the Treatment of Wet AMD

October 2, 2022

REGENXBIO Announces Presentation at Chardan's 6th Annual Genetic Medicines Conference

September 26, 2022

REGENXBIO Announces Upcoming Presentations During the American Academy of Ophthalmology 2022 Annual Meeting

September 25, 2022

REGENXBIO Presents Additional Positive Interim Data from the Phase I/II/III CAMPSIITE™ Trial of RGX-121 for the Treatment of MPS II (Hunter Syndrome) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium

August 30, 2022

REGENXBIO Announces Presentations at the Society for the Study of Inborn Errors of Metabolism Annual Symposium

August 22, 2022

REGENXBIO Announces Presentation at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference

August 9, 2022

REGENXBIO Reports Second Quarter 2022 Financial Results and Recent Operational Highlights

August 2, 2022

REGENXBIO Announces Intention to File a Biologics License Application Using the Accelerated Approval Pathway for RGX-121, an AAV Therapeutic for the Treatment of MPS II

August 2, 2022

REGENXBIO to Host Conference Call on August 3 to Discuss Second Quarter 2022 Financial Results and Recent Operational Highlights

July 31, 2022

REGENXBIO Announces Enrollment Complete in Cohort 5 of Phase II AAVIATE® Trial

July 7, 2022

REGENXBIO Opens State-of-the-Art Gene Therapy Manufacturing Facility

June 8, 2022

Jennifer Zachary Joins REGENXBIO Board of Directors

June 6, 2022

REGENXBIO Reports First Quarter 2022 Financial Results and Recent Operational Highlights

May 3, 2022

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting

May 2, 2022

REGENXBIO to Host Conference Call on May 4 to Discuss First Quarter 2022 Financial Results and Recent Operational Highlights

April 26, 2022

REGENXBIO Announces Presentation at Chardan's 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

April 19, 2022

REGENXBIO Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Operational Highlights

February 28, 2022

REGENXBIO to Host Conference Call on March 1 to Discuss Fourth Quarter and Full-Year 2021 Financial Results and Recent Operational Highlights

February 21, 2022

REGENXBIO Presents Positive Interim Data from Phase II ALTITUDE™ Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery

February 11, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 24 calls. Every call is listed under its year.

Decks

The 5 newest of 21 decks. Every deck is listed under its year.